Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Key Highlights
- ➤Scott Wasserman appointed to Inhibikase’s Board, effective October 19, 2026
- ➤Dennis Berman resigns from Inhibikase’s Board of Directors
- ➤IMPROVE-PAH Phase 3 study of IKT-001 actively enrolling patients
- ➤IKT-001 targets Pulmonary Arterial Hypertension, a progressive, life-threatening disease
Expert Statements
Amit Munshi, Chair of the Inhibikase Board of Directors
“We thank Dennis for his many contributions to the Company during his years of service”
Amit Munshi, Chair of the Inhibikase Board of Directors
“Scott has taken multiple programs from early development through global approval, and he has built clinical organizations at both large and emerging companies”
Amit Munshi, Chair of the Inhibikase Board of Directors
“We look forward to benefiting from his expertise as we continue to advance our global Phase 3 IMPROVE-PAH study of IKT-001. We are pleased to welcome Scott to our Board.”
Scott M. Wasserman, Chief Medical Officer of Kailera Therapeutics and Inhibikase Board member
“PAH is a progressive, life-threatening disease, and the pedigree of imatinib together with the recent preclinical and Phase 1 data for IKT-001 point to a very promising role for this asset in this difficult to treat condition”
Scott M. Wasserman, Chief Medical Officer of Kailera Therapeutics and Inhibikase Board member
“This is an important time for Inhibikase, and I look forward to applying my experience in global clinical development and regulatory interactions as the Company advances IMPROVE-PAH.”
WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s appointment, the Company also announced the resignation of Dennis Berman from the Company’s Board.
“We thank Dennis for his many contributions to the Company during his years of service,” said Amit Munshi, Chair of the Inhibikase Board of Directors.
Get started
Create a free account to read the full story.